HENLIUS News

HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE CLINICAL TRIAL OF HLX53 (ANTI-TIGIT FC FUSION PROTEIN) IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) AND HANBEITAI (BEVACIZUMAB INJECTION) FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC

Apr 17 04:56 ET

HENLIUS: FORM OF PROXY FOR THE 2024 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS AND UNLISTED FOREIGN SHAREHOLDERS TO BE HELD ON MONDAY, 20 MAY 2024

Apr 17 04:40 ET

HENLIUS: FORM OF PROXY FOR THE 2024 FIRST CLASS MEETING OF H SHAREHOLDERS TO BE HELD ON MONDAY, 20 MAY 2024

Apr 17 04:39 ET

HENLIUS: PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, 20 MAY 2024 (OR ANY ADJOURNMENT THEREOF)

Apr 17 04:38 ET

HENLIUS: NOTICE OF THE 2024 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS AND UNLISTED FOREIGN SHAREHOLDERS

Apr 17 04:37 ET

HENLIUS: NOTICE OF THE 2024 FIRST CLASS MEETING OF H SHAREHOLDERS

Apr 17 04:36 ET

HENLIUS: NOTICE OF ANNUAL GENERAL MEETING

Apr 17 04:35 ET

HENLIUS: ANNUAL GENERAL MEETING; RE-APPOINTMENT OF AUDITORS; GRANT OF GENERAL MANDATES TO ISSUE ANY CLASS OF SHARES AND REPURCHASE H SHARES; PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; NOTICES OF AGM AND CLASS MEETINGS

Apr 17 04:34 ET

HENLIUS: 2023 Environmental, Social and Governance Report

Apr 17 04:33 ET

HENLIUS: ANNUAL REPORT 2023

Apr 17 04:32 ET

HENLIUS: VOLUNTARY ANNOUNCEMENT - AN INTERNATIONAL MULTI-CENTRE PHASE 3 CLINICAL STUDY OF A BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY INJECTION) FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT HIGH RISK FO

Apr 5 06:00 ET

HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

Apr 3 04:51 ET

HENLIUS: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

Mar 21 05:24 ET

HENLIUS: PROPOSED CHANGE OF REGISTERED ADDRESS IN CHINA AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Mar 21 05:00 ET

HENLIUS: VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX42 FOR INJECTION (ANTIBODY-DRUG CONJUGATE TARGETING EGFR WITH NOVEL DNA TOPOISOMERASE I INHIBITOR) FOR THE TREATMENT OF ADVANCE/METASTATIC SOLID TUMOURS IN

Mar 14 09:00 ET

HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF HLX6018 WAS APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Mar 12 06:20 ET

HENLIUS: DATE OF BOARD MEETING

Mar 11 05:00 ET

HENLIUS: INSIDE INFORMATION ANNOUNCEMENT - POSITIVE PROFIT ALERT

Mar 4 05:03 ET

HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

Mar 1 04:44 ET

HENLIUS: VOLUNTARY ANNOUNCEMENT - THE SUPPLEMENTAL APPLICATIONS OF HANDAYUAN (ADALIMUMAB INJECTION) FOR THE NEW INDICATIONS HAVE BEEN ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Feb 29 04:00 ET